Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5760849 | 0.87 | LMNA (0.35) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL3877614 | 0.81 | DPP4 (0.40) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Trifluoroacetic Acid SCHEMBL3874704 | 0.71 | DPP4 (0.39) | P2RX3 | |
| SCHEMBL13875677 | 0.70 | P2RX3 (0.43) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL13876123 | 0.69 | P2RX3 (0.42) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL3875374 | 0.69 | DPP4 (0.38) | — | |
| SCHEMBL3874710 | 0.68 | DPP4 (0.37) | — | |
| SCHEMBL13866897 | 0.68 | DPP4 (0.43) | P2RX3 | |
| Trifluoroacetic Acid SCHEMBL3877608 | 0.68 | DPP4 (0.41) | P2RX3 | |
| SCHEMBL5774800 | 0.67 | DPP4 (0.50) | LMNACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | EISAI CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111362-A1 | 1,3-Dihydroimidazole ring compound | NR2C2, NR0B2, DPP4 | LMNA 4752/4885CYP2C9 1454/4885ATP6V1B2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.